Savient announces shipping date for chronic gout treatment

EAST BRUNSWICK, N.J. Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors at the end of this month, Savient said.

The company announced that it would begin shipping Krystexxa (pegloticase) on Nov. 30, and it would become available for prescription on Dec. 1.

“The commercial availability of Krystexxa marks another significant milestone for both patients and the company, as it is the first FDA-approved therapy that addresses a significant unmet medical need in the treatment of chronic gout in adult patients refractory to conventional therapy,” Savient president Paul Hamelin said in a statement.